ATS 2024 Final Program

Click on the session title to view the speakers

108

SUNDAY • MAYs 19

720 Anti-TSLP Treatment Modulates Pulmonary Response in an Experimental Model of Asthma COPD Overlap 721 Cell-Free DNA to Predict Severe Exacerbations in Chronic Obstructive Pulmonary Disease 722 The Prevalence of Type 2 Airway Inflammation in COPD Based on Bronchoalveolar Lavage Fluid 723 On-chip Reconstitution of Hematopoietic Niche for Real-time Leukocyte Mobilization Analysis 724 Leveraging Machine Learning and Real-world Data to Predict Chronic Obstructive Pulmonary Disease Exacerbations A102 EVALUATING THE INTERSECTION BETWEEN AUTOIMMUNITY, IMMUNODEFICIENCY, AND INTERSTITIAL LUNG DISEASES 2:15 p.m. - 4:15 p.m. San Diego Convention Center Room 31A-C (Upper Level) Poster Viewing 2:15-3:00 Discussion 3:00-4:15 801 Efzofitimod Is an Immunomodulator of Myeloid Cell Function and Novel Therapeutic Candidate for Interstitial Lung Diseases 802 Longitudinal Effects of Localized Radiotherapy on Interstitial Lung Disease: Proof-of-Concept Study in Animal Models 803 Biologic Prescribing Patterns in ABPA: Data From a Large Academic Center 804 C-reactive Protein as a Biomarker for Systemic Sclerosis-associated Interstitial Lung Disease: Re-envisioning Clinical Trial Enrichment Strategies Based on Evidence 805 Tacrolimus in a U.S. Cohort of Myositis Related Interstitial Lung Disease 806 Serum Protein Levels of the CXCL9, CXCL10, and CXCL11 Chemokines Reflect Sarcoidosis Disease Severity in the GRADS Cohort BASIC • CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

807 Enhanced T Cell ‘Stem-ness’ in Secondary Lymphoid Compartment of Patients With Idiopathic Pulmonary Fibrosis 808 A Genome-wide Association Study of Eosinophilic Granulomatosis With Polyangiitis Identifies Two Novel Disease Susceptibility Loci 809 Association of Interstitial Lung Disease With a Severe Pulmonary and Immunological Phenotype in Common Variable Immunodeficiency 810 Calcaratarin D, A Labdane Diterpenoid, Attenuates Bleomycin-induced Pulmonary Fibrosis by Blocking WNT/beta-catenin Signaling Pathway 811 Quantification of Myositis-specific Autoantibodies in Idiopathic Inflammatory Myopathy-associated Interstitial Lung Disease Using the Luciferase Immunoprecipitation System (LIPS): Implications for Disease Severity and Treatment Response 812 Dysregulated Host Response Is Seen in Idiopathic Pulmonary Fibrosis and Is Associated With Reduced Transplant-free Survival 813 Quantitative Digital Pathology and AI Method Characterize the Histologic Phenotypes of Fibrosis Severity in Bleomycin-Induced Lung Fibrosis Mouse Model 814 Vaccination With the BNT162b2 MRNA Vaccine as an Immune Stimulus Highlights Variable Cell Proportion Trends in Sarcoidosis 815 Airway Epithelial Responses to Cutibacterium Acnes in Sarcoidosis 816 Discovery of the Novel Selective and Orally Bioavailable CXCR7 Modulator for the Treatment of Idiopathic Pulmonary Fibrosis 817 Hedgehog Activation Promotes Fibroblast-macrophage Interaction in the IPF Lung 818 Inhibition of Protein Disulfide Isomerase A3 and Osteopontin Attenuates Influenza-induced Lung Fibrosis 819 Gut Microbiota Induces Pulmonary CD4+ IL-6+ Expression Through PD-1/HIF-1 a Signaling in Mice

ATS 2024 Conference Program • San Diego, CA